Cabaletta Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2020

Financial Assets Measured at Fair Value on Recurring Basis

The following tables present financial information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:

	September 30, 2020
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial assets
Cash and cash equivalents:
Cash and money market funds	$	108,679	$	108,679	$	—	$	—
Short-term investments:
Corporate bonds		8,062		—		8,062		—
Long-term investments:
Corporate bonds		1,333		—		1,333		—
Total	$	118,074	$	108,679	$	9,395	$	—

	December 31, 2019
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial assets
Cash and cash equivalents:
Cash and money market funds	$	136,204	$	136,204	$	—	$	—
Total	$	136,204	$	136,204	$	—	$	—

Schedule of Debt Securities Classified as Available-for-Sale Investments

	September 30, 2020
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair value
Financial assets
Cash and money market funds
Included in cash and cash equivalents	$	108,679	$	—	$	—	$	108,679
Corporate bonds - due in one year or less
Included in short-term investments		8,051		11		—		8,062
Corporate bonds - due between one to two years
Included in long-term investments		1,332		1		—		1,333
Total	$	118,062	$	12	$	—	$	118,074